You just read:

AbbVie Presents Results from Phase 1 Studies of Investigational Compound Venetoclax in Patients with Multiple Myeloma at the American Society of Clinical Oncology Annual Meeting

News provided by

AbbVie

May 31, 2015, 08:00 ET